{"id":745685,"date":"2018-07-31T05:30:00","date_gmt":"2018-07-31T05:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/"},"modified":"2025-11-07T01:27:08","modified_gmt":"2025-11-07T06:27:08","slug":"eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/","title":{"rendered":"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma"},"content":{"rendered":"<p>\n      Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United<br \/>\n      States and Canada, announced today that the U.S. Food and Drug<br \/>\n      Administration (FDA) granted Breakthrough Therapy designation for LENVIMA<sup>\u00ae<\/sup><br \/>\n      (lenvatinib), the orally available kinase inhibitor discovered by Eisai,<br \/>\n      in combination with Merck&#8217;s anti-PD-1 therapy KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab) for the potential treatment of patients with advanced<br \/>\n      and\/or metastatic non-microsatellite instability high (MSI-H)\/proficient<br \/>\n      mismatch repair (pMMR) endometrial carcinoma (EC) who have progressed<br \/>\n      following at least one prior systemic therapy. The LENVIMA\/KEYTRUDA<br \/>\n      combination therapy is being jointly developed by Eisai and Merck as<br \/>\n      part of the strategic collaboration announced in March 2018. This is the<br \/>\n      third Breakthrough Therapy designation for LENVIMA and the second<br \/>\n      Breakthrough Therapy designation for LENVIMA in combination with<br \/>\n      KEYTRUDA, following the Breakthrough Therapy designation for the<br \/>\n      combination for advanced and\/or metastatic renal cell carcinoma<br \/>\n      announced in January 2018.\n    <\/p>\n<p>\n      The Breakthrough Therapy designation is an FDA program intended to<br \/>\n      expedite development and review of medicines for serious or<br \/>\n      life-threatening conditions. In order to qualify for this designation,<br \/>\n      preliminary clinical evidence must demonstrate that the drug may provide<br \/>\n      substantial improvement over currently available therapy on at least one<br \/>\n      clinically significant endpoint. The benefits of this Breakthrough<br \/>\n      Therapy designation include more intensive guidance on an efficient<br \/>\n      clinical development program, access to senior FDA managers and<br \/>\n      experienced FDA staff to help accelerate review time, as well as<br \/>\n      eligibility for rolling review and potentially priority review.\n    <\/p>\n<p>\n      This Breakthrough Therapy designation was based on interim results of<br \/>\n      the EC cohort in Study 111\/KEYNOTE-146, which were presented in June<br \/>\n      2018 at the 54<sup>th<\/sup> American Society of Clinical Oncology (ASCO)<br \/>\n      Annual Meeting. Study 111\/KEYNOTE-146 is a multicenter, open-label,<br \/>\n      single-arm Phase 1b\/2 basket trial evaluating the efficacy and safety of<br \/>\n      LENVIMA in combination with KEYTRUDA in patients with selected solid<br \/>\n      tumors.\n    <\/p>\n<p>\n      \u201cThis second Breakthrough Therapy designation for the LENVIMA\/KEYTRUDA<br \/>\n      combination represents another step forward in our collaboration with<br \/>\n      Eisai and supports the continued evaluation of this combination in more<br \/>\n      than 11 types of cancer,\u201d said Dr. Roy Baynes, senior vice president and<br \/>\n      head of global clinical development, chief medical officer, Merck<br \/>\n      Research Laboratories. \u201cWe will continue to work closely with Eisai to<br \/>\n      build on the robust data for the LENVIMA\/KEYTRUDA combination in<br \/>\n      advanced endometrial carcinoma in an effort to offer a new option for<br \/>\n      these patients and potentially help address a critical unmet need.\u201d\n    <\/p>\n<p>\n      \u201cWe designed Study 111 to learn as much as we could about the<br \/>\n      LENVIMA\/KEYTRUDA combination as efficiently as possible, driven by a<br \/>\n      sense of urgency to bring forward a potential new treatment option for<br \/>\n      patients in need,\u201d said Dr. Takashi Owa, Vice President and Chief<br \/>\n      Medicine Creation Officer, Oncology Business Group, Eisai. \u201cWe are<br \/>\n      encouraged by the continued activity seen in patients with endometrial<br \/>\n      carcinoma, and the latest Breakthrough Therapy designation for LENVIMA<br \/>\n      and KEYTRUDA has strengthened our commitment, as part of our <i>human<br \/>\n      health care<\/i> mission, to expedite the path to ultimately benefitting<br \/>\n      patients living with endometrial carcinoma as quickly as possible.\u201d\n    <\/p>\n<p>\n      The combination of LENVIMA and KEYTRUDA is investigational. The efficacy<br \/>\n      and safety of this combination has not been established. The<br \/>\n      LENVIMA\/KEYTRUDA combination is not approved in any cancer types today.\n    <\/p>\n<p>\n      <b>About Study 111\/KEYNOTE-146<\/b>\n    <\/p>\n<p>\n      Study 111\/KEYNOTE-146 is a multicenter, open-label, single-arm Phase<br \/>\n      1b\/2 basket trial evaluating the combination of LENVIMA (20 mg\/day) with<br \/>\n      KEYTRUDA (200 mg intravenously every three weeks) in patients with<br \/>\n      selected solid tumors (renal cell carcinoma, EC, non-small cell lung<br \/>\n      cancer, urothelial cancer, squamous cell head and neck cancer, and<br \/>\n      melanoma). Patients were not preselected based on MSI or PD-L1 tumor<br \/>\n      biomarker status. The primary endpoint of the Phase 1b study was to<br \/>\n      determine the maximum tolerated dose of LENVIMA and KEYTRUDA in<br \/>\n      combination. The primary endpoint of the Phase 2 portion is<br \/>\n      investigator-assessed objective response rate (ORR) at week 24 based on<br \/>\n      immune-related RECIST (irRECIST). The secondary efficacy endpoints<br \/>\n      included ORR, progression-free survival and duration of response for<br \/>\n      patients with complete or partial responses. Fifty-three patients with<br \/>\n      previously treated, metastatic EC were evaluated in the EC cohort.<br \/>\n      Currently, the Phase 2 part is ongoing, as an EC cohort expansion. This<br \/>\n      study is being conducted under an existing strategic collaboration<br \/>\n      between the two companies.\n    <\/p>\n<p>\n      A randomized, international, two-arm Phase 3 study in recurrent EC is<br \/>\n      underway (Study 309\/KEYNOTE-775; NCT03517449; please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03517449&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=clinicaltrials.gov&amp;index=1&amp;md5=9d9ae1257d7e64dbc806f85dea956e44\" rel=\"nofollow\">clinicaltrials.gov<\/a><br \/>\n      for more information).\n    <\/p>\n<p>\n      <b>About Endometrial Carcinoma<\/b>\n    <\/p>\n<p>\n      Endometrial cancer begins in the inner lining of the uterus<br \/>\n      (endometrium), and nearly all cancers of the uterus are endometrial<br \/>\n      carcinomas. In 2018, it is estimated there will be approximately 63,230<br \/>\n      new cases of uterine cancer, and there will be approximately 11,350<br \/>\n      deaths from uterine cancer (with the figures for endometrial cancer<br \/>\n      being slightly lower than this combined estimate). Stages of endometrial<br \/>\n      cancer range from stage 1 through 4. The five-year survival rate for<br \/>\n      women diagnosed with stage 1A endometrial cancer is 88% and drops to 15%<br \/>\n      for those diagnosed with stage 4B.\n    <\/p>\n<p>\n      <b>About the Eisai and Merck Strategic Collaboration<\/b>\n    <\/p>\n<p>\n      In March 2018, Eisai and Merck, through an affiliate, entered into a<br \/>\n      strategic collaboration for the worldwide co-development and<br \/>\n      co-commercialization of LENVIMA. Under the agreement, the companies will<br \/>\n      develop and commercialize LENVIMA jointly, both as monotherapy and in<br \/>\n      combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA. In addition to<br \/>\n      ongoing clinical studies of the combination, the companies will jointly<br \/>\n      initiate new clinical studies evaluating the combination to support 11<br \/>\n      potential indications in six types of cancer (bladder cancer,<br \/>\n      endometrial cancer, head and neck cancer, hepatocellular carcinoma,<br \/>\n      melanoma and non-small cell lung cancer), as well as a basket trial<br \/>\n      targeting six additional cancer types. The combination is not approved<br \/>\n      in any cancer types today.\n    <\/p>\n<p>\n      <b>About LENVIMA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>\u00a0(lenvatinib)<\/b>\u00a0<b>capsules<br \/>\n      4 mg and 10 mg<\/b>\n    <\/p>\n<p>\n      LENVIMA<sup>\u00ae<\/sup>\u00a0(lenvatinib) is a kinase inhibitor that is indicated<br \/>\n      for:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Differentiated Thyroid Cancer (DTC): single agent for patients with<br \/>\n        locally recurrent or metastatic, progressive, radioactive<br \/>\n        iodine-refractory DTC.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Renal Cell Cancer (RCC): in combination with everolimus for patients<br \/>\n        with advanced RCC following one prior anti-angiogenic therapy.\n      <\/li>\n<\/ul>\n<p>\n      LENVIMA, discovered and developed by Eisai, is a kinase inhibitor that<br \/>\n      inhibits the kinase activities of vascular endothelial growth factor<br \/>\n      (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA<br \/>\n      inhibits other kinases that have been implicated in pathogenic<br \/>\n      angiogenesis, tumor growth, and cancer progression in addition to their<br \/>\n      normal cellular functions, including fibroblast growth factor (FGF)<br \/>\n      receptors FGFR1-4; the platelet derived growth factor receptor alpha<br \/>\n      (PDGFR\u03b1), KIT, and RET.\n    <\/p>\n<p>\n      <b>Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In DTC, hypertension was reported in 73% of patients on LENVIMA vs 16%<br \/>\n        with placebo (44% vs 4% grade \u22653). In RCC, hypertension was reported<br \/>\n        in 42% of patients on LENVIMA + everolimus vs 10% with everolimus<br \/>\n        alone (13% vs 2% grade 3). Serious complications of poorly controlled<br \/>\n        hypertension have been reported. Systolic blood pressure \u2265160 mmHg<br \/>\n        occurred in 29% of patients, and 21% of patients had a diastolic blood<br \/>\n        pressure \u2265100 mmHg in the LENVIMA + everolimus\u2013 treated group. Blood<br \/>\n        pressure should be controlled prior to treatment and monitored<br \/>\n        throughout. Withhold dose for grade 3 hypertension despite optimal<br \/>\n        antihypertensive therapy; resume at reduced dose when controlled at<br \/>\n        grade \u22642. Discontinue for life-threatening hypertension\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, cardiac dysfunction was reported in 7% of patients on LENVIMA<br \/>\n        vs 2% with placebo (2% vs 0% grade \u22653). In RCC, decreased ejection<br \/>\n        fraction and cardiac failure were reported in 10% of patients on<br \/>\n        LENVIMA + everolimus vs 6% with everolimus alone (3% vs 2% grade 3).<br \/>\n        Monitor for signs\/symptoms of cardiac decompensation. Withhold LENVIMA<br \/>\n        for development of grade 3 cardiac dysfunction until improvement to<br \/>\n        grade 0, 1, or baseline. Resume at reduced dose or discontinue based<br \/>\n        on severity and persistence of cardiac dysfunction. Discontinue for<br \/>\n        grade 4 cardiac dysfunction\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, arterial thromboembolic events were reported in 5% of patients<br \/>\n        on LENVIMA vs 2% with placebo (3% vs 1% grade \u22653). In RCC, arterial<br \/>\n        thromboembolic events were reported in 2% of patients on LENVIMA +<br \/>\n        everolimus vs 6% with everolimus alone (2% vs 4% grade \u22653).<br \/>\n        Discontinue following an arterial thrombotic event. The safety of<br \/>\n        resuming LENVIMA after an arterial thromboembolic event has not been<br \/>\n        established, and LENVIMA has not been studied in patients who have had<br \/>\n        an arterial thromboembolic event within the previous 6 months\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical studies in which 1,160 patients received LENVIMA<br \/>\n        monotherapy, hepatic failure (including fatal events) was reported in<br \/>\n        3 patients and acute hepatitis in 1 patient. In DTC, ALT and AST<br \/>\n        increases (grade \u22653) occurred in 4% and 5% of patients on LENVIMA,<br \/>\n        respectively, vs 0% with placebo. In RCC, ALT and AST increases (grade<br \/>\n        \u22653) occurred in 3% of patients on LENVIMA + everolimus vs 2% and 0%<br \/>\n        with everolimus alone, respectively. Monitor liver function before<br \/>\n        initiation, then every 2 weeks for the first 2 months, and at least<br \/>\n        monthly thereafter during treatment. Withhold dose for liver<br \/>\n        impairment grade \u22653 until resolved to grade 0, 1, or baseline. Resume<br \/>\n        at reduced dose or discontinue based on severity\/persistence of<br \/>\n        hepatotoxicity. Discontinue for hepatic failure\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, proteinuria was reported in 34% of patients on LENVIMA vs 3%<br \/>\n        with placebo (11% vs 0% grade 3). In RCC, proteinuria was reported in<br \/>\n        31% of patients on LENVIMA + everolimus vs 14% with everolimus alone<br \/>\n        (8% vs 2% grade 3). Monitor for proteinuria before and during<br \/>\n        treatment. Withhold dose for proteinuria \u22652 g\/24 h. Resume at reduced<br \/>\n        dose when proteinuria is &lt;2 g\/24 h. Discontinue for nephrotic syndrome\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In RCC, diarrhea was reported in 81% of patients on LENVIMA +<br \/>\n        everolimus vs 34% with everolimus alone (19% vs 2% grade \u22653). Initiate<br \/>\n        prompt medical management for the development of diarrhea. Monitor for<br \/>\n        dehydration. Withhold dose for diarrhea grade \u22653. Resume at a reduced<br \/>\n        dose when diarrhea resolves to grade 1 or baseline. Permanently<br \/>\n        discontinue LENVIMA for grade 4 diarrhea despite medical management\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, events of renal impairment were reported in 14% of patients on<br \/>\n        LENVIMA vs 2% with placebo (3% vs 1% grade \u22653). In RCC, events of<br \/>\n        renal impairment were reported in 18% of patients on LENVIMA +<br \/>\n        everolimus vs 12% with everolimus alone (10% vs 2% grade \u22653). Withhold<br \/>\n        LENVIMA for grade 3 or 4 renal failure\/impairment. Resume at reduced<br \/>\n        dose or discontinue, depending on severity\/persistence of renal<br \/>\n        impairment. Active management of diarrhea and any other<br \/>\n        gastrointestinal (GI) symptoms should be initiated for grade 1 events\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, events of GI perforation or fistula were reported in 2% of<br \/>\n        patients on LENVIMA vs 0.8% with placebo. In RCC, events of GI<br \/>\n        perforation, abscess, or fistula (grade \u22653) were reported in 2% of<br \/>\n        patients on LENVIMA + everolimus vs 0% with everolimus alone. Fistulas<br \/>\n        and GI perforations have also been reported in other lenvatinib<br \/>\n        clinical trials and in postmarketing experience. Pneumothorax has been<br \/>\n        reported with and without clear evidence of a bronchopleural fistula.<br \/>\n        Some reports of GI perforation, fistula, and pneumothorax occurred in<br \/>\n        association with tumor regression or necrosis. In most cases of<br \/>\n        fistula formation or GI perforation, risk factors such as prior<br \/>\n        surgery or radiotherapy were present. Discontinue in patients who<br \/>\n        develop GI perforation or life-threatening fistula\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, QT\/QTc interval prolongation was reported in 9% of patients on<br \/>\n        LENVIMA vs 2% with placebo (2% vs 0% &gt;500 ms). In RCC, QTc interval<br \/>\n        increases &gt;60 ms were reported in 11% of patients on LENVIMA +<br \/>\n        everolimus (6% &gt;500 ms) vs 0% with everolimus alone. Monitor<br \/>\n        electrocardiograms in patients with congenital long QT syndrome,<br \/>\n        congestive heart failure, bradyarrhythmias, or patients taking drugs<br \/>\n        known to prolong the QT interval. Monitor and correct electrolyte<br \/>\n        abnormalities in all patients. Withhold dose for QTc interval<br \/>\n        prolongation &gt;500 ms. Resume at reduced dose when QTc prolongation<br \/>\n        resolves to baseline\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, hypocalcemia (grade \u22653) was reported in 9% of patients on<br \/>\n        LENVIMA vs 2% with placebo. In RCC, hypocalcemia (grade \u22653) was<br \/>\n        reported in 6% of patients on LENVIMA + everolimus vs 2% with<br \/>\n        everolimus alone. Monitor blood calcium levels at least monthly and<br \/>\n        replace calcium as necessary. Interrupt and adjust LENVIMA as necessary\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical studies in which 1,160 patients received LENVIMA<br \/>\n        monotherapy, reversible posterior leukoencephalopathy syndrome (RPLS)<br \/>\n        was reported in 4 patients. Withhold LENVIMA for RPLS until fully<br \/>\n        resolved. Resume at reduced dose or discontinue based on the severity<br \/>\n        and persistence of neurologic symptoms\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical studies in which 1,160 patients received LENVIMA<br \/>\n        monotherapy, hemorrhage (grade\u22653) was reported in 2% of patients. In<br \/>\n        DTC, hemorrhagic events occurred in 35% of patients on LENVIMA vs 18%<br \/>\n        with placebo (2% vs 3% grade \u22653). There was 1 fatal intracranial<br \/>\n        hemorrhage case among 16 patients who received LENVIMA and had central<br \/>\n        nervous system metastases at baseline. The most frequently reported<br \/>\n        hemorrhagic event was epistaxis (11% grade 1, 1% grade 2).<br \/>\n        Discontinuation due to hemorrhagic events occurred in 1% of patients<br \/>\n        on LENVIMA. In RCC, hemorrhagic events occurred in 34% of patients on<br \/>\n        LENVIMA + everolimus vs 26% with everolimus alone (8% vs 2% grade \u22653).<br \/>\n        The most frequently reported hemorrhagic event was epistaxis (23% for<br \/>\n        LENVIMA + everolimus vs 24% with everolimus alone). There was 1 fatal<br \/>\n        cerebral hemorrhage case. Discontinuation due to hemorrhagic events<br \/>\n        occurred in 3% of patients on LENVIMA + everolimus. Consider the risk<br \/>\n        of severe or fatal hemorrhage associated with tumor<br \/>\n        invasion\/infiltration of major blood vessels (eg, carotid artery).<br \/>\n        Withhold LENVIMA for the development of grade 3 hemorrhage until<br \/>\n        resolved to grade 0 or 1. Resume at reduced dose or discontinue based<br \/>\n        on severity\/persistence of hemorrhage. Discontinue for grade 4<br \/>\n        hemorrhage\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC patients with normal baseline thyroid-stimulating hormone<br \/>\n        (TSH), elevation of TSH level above 0.5 mU\/L was observed postbaseline<br \/>\n        in 57% of patients on LENVIMA vs 14% with placebo. In RCC, grade 1 or<br \/>\n        2 hypothyroidism occurred in 24% of patients on LENVIMA + everolimus<br \/>\n        vs 2% with everolimus alone. In RCC patients with normal or low TSH at<br \/>\n        baseline, elevation of TSH was observed postbaseline in 60% of<br \/>\n        patients on LENVIMA + everolimus vs 3% with everolimus alone. Monitor<br \/>\n        thyroid function before initiation of and at least monthly throughout<br \/>\n        treatment. Treat hypothyroidism according to standard medical practice<br \/>\n        to maintain a euthyroid state\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Wound healing complications, including fistula formation and wound<br \/>\n        dehiscence, can occur with LENVIMA. Withhold LENVIMA for at least 6<br \/>\n        days prior to scheduled surgery. Resume LENVIMA after surgery based on<br \/>\n        clinical judgment of adequate wound healing. Permanently discontinue<br \/>\n        LENVIMA in patients with wound healing complications\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        LENVIMA can cause fetal harm when administered to a pregnant woman.<br \/>\n        Advise females of reproductive potential to use effective<br \/>\n        contraception during treatment with LENVIMA and for at least 2 weeks<br \/>\n        following completion of therapy\n      <\/li>\n<\/ul>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In DTC, the most common adverse reactions (\u226530%) observed in<br \/>\n        LENVIMA-treated patients vs placebo-treated patients were hypertension<br \/>\n        (73% vs 16%), fatigue (67% vs 35%), diarrhea (67% vs 17%),<br \/>\n        arthralgia\/myalgia (62% vs 28%), decreased appetite (54% vs 18%),<br \/>\n        weight decreased (51% vs 15%), nausea (47% vs 25%), stomatitis (41% vs<br \/>\n        8%), headache (38% vs 11%), vomiting (36% vs 15%), proteinuria (34% vs<br \/>\n        3%), palmar-plantar erythrodysesthesia syndrome (32% vs 1%), abdominal<br \/>\n        pain (31% vs 11%), and dysphonia (31% vs 5%)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, adverse reactions led to dose reductions in 68% of patients<br \/>\n        receiving LENVIMA and in 5% of patients receiving placebo; 18% of<br \/>\n        patients discontinued LENVIMA and 5% discontinued placebo for adverse<br \/>\n        reactions. The most common adverse reactions (\u226510%) resulting in dose<br \/>\n        reductions of LENVIMA were hypertension (13%), proteinuria (11%),<br \/>\n        decreased appetite (10%), and diarrhea (10%); the most common adverse<br \/>\n        reactions (\u22651%) resulting in discontinuation of LENVIMA were<br \/>\n        hypertension (1%) and asthenia (1%)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In RCC, the most common adverse reactions (&gt;30%) observed in patients<br \/>\n        treated with LENVIMA + everolimus vs everolimus alone were diarrhea<br \/>\n        (81% vs 34%), fatigue (73% vs 40%), arthralgia\/myalgia (55% vs 32%),<br \/>\n        decreased appetite (53% vs 18%), vomiting (48% vs 12%), nausea (45% vs<br \/>\n        16%), stomatitis\/oral inflammation (44% vs 50%),<br \/>\n        hypertension\/increased blood pressure (42% vs 10%), peripheral edema<br \/>\n        (42% vs 20%), cough (37% vs 30%), abdominal pain (37% vs 8%),<br \/>\n        dyspnea\/exertional dyspnea (35% vs 28%), rash (35% vs 40%), weight<br \/>\n        decreased (34% vs 8%), hemorrhagic events (32% vs 26%), and<br \/>\n        proteinuria\/urine protein present (31% vs 14%). The most common<br \/>\n        serious adverse reactions (\u22655%) were renal failure (11%), dehydration<br \/>\n        (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting<br \/>\n        (5%), and dyspnea (5%)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In RCC, adverse reactions led to dose reductions or interruption in<br \/>\n        89% of patients receiving LENVIMA + everolimus and in 54% of patients<br \/>\n        receiving everolimus alone. The most common adverse reactions (\u22655%)<br \/>\n        resulting in dose reductions in the LENVIMA + everolimus\u2013treated group<br \/>\n        were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting<br \/>\n        (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due<br \/>\n        to an adverse reaction occurred in 29% of patients in the LENVIMA +<br \/>\n        everolimus\u2013treated group and in 12% of patients in the<br \/>\n        everolimus-treated group\n      <\/li>\n<\/ul>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Because of the potential for serious adverse reactions in nursing<br \/>\n        infants, advise women to discontinue breastfeeding during treatment\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        LENVIMA may result in reduced fertility in females of reproductive<br \/>\n        potential and may result in damage to male reproductive tissues,<br \/>\n        leading to reduced fertility of unknown duration\n      <\/li>\n<\/ul>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>\u00a0(pembrolizumab) Injection,<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program, which currently involves more than 750 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab) Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression. In pediatric<br \/>\n      patients with PMBCL, KEYTRUDA is administered at a dose of 2 mg\/kg (up<br \/>\n      to a maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [Combined Positive Score (CPS) \u226510], or in patients who are not eligible<br \/>\n      for any platinum-containing chemotherapy regardless of PD-L1 status.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and duration of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is a fixed dose of<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      The incidence of new or worsening hypothyroidism was higher in patients<br \/>\n      with HNSCC, occurring in 28 (15%) of 192 patients with HNSCC, including<br \/>\n      Grade 3 (0.5%) hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis.<br \/>\n      Monitor patients for changes in thyroid function (at the start of<br \/>\n      treatment, periodically during treatment, and as indicated based on<br \/>\n      clinical evaluation) and for clinical signs and symptoms of thyroid<br \/>\n      disorders. Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA.<br \/>\n      While immune-mediated adverse reactions usually occur during treatment<br \/>\n      with PD-1\/PD-L1 blocking antibodies, they may occur after<br \/>\n      discontinuation of treatment. For suspected immune-mediated adverse<br \/>\n      reactions, ensure adequate evaluation to confirm etiology or exclude<br \/>\n      other causes. Based on the severity of the adverse reaction, withhold<br \/>\n      KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials, including cHL, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after treatment with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 developed<br \/>\n      graft-versus-host disease (GVHD) (one fatal case), and 2 developed<br \/>\n      severe hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning (one fatal case). Cases of fatal hyperacute GVHD after<br \/>\n      allogeneic HSCT have also been reported in patients with lymphoma who<br \/>\n      received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      Follow patients closely for early evidence of transplant-related<br \/>\n      complications such as hyperacute GVHD, Grade 3 to 4 acute GVHD,<br \/>\n      steroid-requiring febrile syndrome, hepatic VOD, and other<br \/>\n      immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD, including<br \/>\n      fatal GVHD, has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 23% of patients; the most common (\u22651%) were<br \/>\n      diarrhea (1%), fatigue (1.3%), pneumonia (1%), liver enzyme elevation<br \/>\n      (1.2%), decreased appetite (1.3%), and pneumonitis (1%). The most common<br \/>\n      adverse reactions (occurring in at least 20% of patients and at a higher<br \/>\n      incidence than with docetaxel) were decreased appetite (25% vs 23%),<br \/>\n      dyspnea (23% vs 20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      In KEYNOTE-021(G1), when KEYTRUDA was administered in combination with<br \/>\n      carboplatin and pemetrexed (carbo\/pem) in advanced nonsquamous NSCLC,<br \/>\n      KEYTRUDA was discontinued in 10% of 59 patients. The most common adverse<br \/>\n      reaction resulting in discontinuation of KEYTRUDA (\u22652%) was acute kidney<br \/>\n      injury (3.4%). Adverse reactions leading to interruption of KEYTRUDA<br \/>\n      occurred in 39% of patients; the most common (\u22652%) were fatigue (8%),<br \/>\n      neutrophil count decreased (8%), anemia (5%), dyspnea (3.4%), and<br \/>\n      pneumonitis (3.4%). The most common adverse reactions (\u226520%) with<br \/>\n      KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs 50%), nausea<br \/>\n      (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%), vomiting<br \/>\n      (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%), decreased<br \/>\n      appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs 18%),<br \/>\n      dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs 4.8%),<br \/>\n      peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia (20% vs<br \/>\n      3.2%), upper respiratory tract infection (20% vs 3.2%), and arthralgia<br \/>\n      (15% vs 24%). This study was not designed to demonstrate a statistically<br \/>\n      significant difference in adverse reaction rates for KEYTRUDA as<br \/>\n      compared to carbo\/pem alone for any specified adverse reaction.\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL, and treatment was interrupted due to adverse<br \/>\n      reactions in 26% of patients. Fifteen percent (15%) of patients had an<br \/>\n      adverse reaction requiring systemic corticosteroid therapy. Serious<br \/>\n      adverse reactions occurred in 16% of patients. The most frequent serious<br \/>\n      adverse reactions (\u22651%) included pneumonia, pneumonitis, pyrexia,<br \/>\n      dyspnea, GVHD, and herpes zoster. Two patients died from causes other<br \/>\n      than disease progression; one from GVHD after subsequent allogeneic HSCT<br \/>\n      and one from septic shock. The most common adverse reactions (occurring<br \/>\n      in \u226520% of patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL, and treatment was interrupted due to adverse<br \/>\n      reactions in 15%. Twenty-five percent (25%) of patients had an adverse<br \/>\n      reaction requiring systemic corticosteroid therapy. Serious adverse<br \/>\n      reactions occurred in 26% of patients and included: arrhythmia (4%),<br \/>\n      cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion<br \/>\n      (2%), and pericarditis (2%). Six (11%) patients died within 30 days of<br \/>\n      start of treatment. The most common adverse reactions (occurring in \u226520%<br \/>\n      of patients) were musculoskeletal pain (30%), upper respiratory tract<br \/>\n      infection and pyrexia (28% each), cough (26%), fatigue (23%), and<br \/>\n      dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in \u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (\u226520%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients (in Cohort E) with recurrent or metastatic cervical<br \/>\n      cancer. Serious adverse reactions occurred in 39% of patients receiving<br \/>\n      KEYTRUDA. The most frequent serious adverse reactions reported included<br \/>\n      anemia (7%), fistula, hemorrhage, and infections [except urinary tract<br \/>\n      infections] (4.1% each). The most common adverse reactions (occurring in<br \/>\n      \u226520% of patients) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors were administered KEYTRUDA 2 mg\/kg every 3 weeks. Patients<br \/>\n      received KEYTRUDA for a median of 3 doses (range 1\u201317 doses), with 34<br \/>\n      patients (85%) receiving 2 doses or more. The safety profile in these<br \/>\n      pediatric patients was similar to that seen in adults treated with<br \/>\n      KEYTRUDA. Toxicities that occurred at a higher rate (\u226515% difference) in<br \/>\n      these patients when compared to adults under 65 years of age were<br \/>\n      fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>About Eisai Inc.<\/b>\n    <\/p>\n<p>\n      At Eisai Inc., <i>human health care<\/i> (<i>hhc<\/i>) is our goal. We<br \/>\n      give our first thoughts to patients and their families, and helping to<br \/>\n      increase the benefits health care provides. As the U.S. pharmaceutical<br \/>\n      subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate<br \/>\n      commitment to patient care that is the driving force behind our efforts<br \/>\n      to discover and develop innovative therapies to help address unmet<br \/>\n      medical needs.\n    <\/p>\n<p>\n      Eisai is a fully integrated pharmaceutical business that operates in two<br \/>\n      global business groups: oncology and neurology (dementia-related<br \/>\n      diseases and neurodegenerative diseases). Each group functions as an<br \/>\n      end-to-end global business with discovery, development, manufacturing<br \/>\n      and marketing capabilities. Our U.S. headquarters, commercial and<br \/>\n      clinical development organizations are located in New Jersey; our<br \/>\n      discovery labs are in Massachusetts and Pennsylvania; and our global<br \/>\n      demand chain organization resides in Maryland and North Carolina. To<br \/>\n      learn more about Eisai Inc., please visit us at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fus.eisai.com%2F&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=eisai.com%2Fus&amp;index=2&amp;md5=526bd8b36fcb65213efcccdea88bee40\" rel=\"nofollow\">eisai.com\/us<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=3&amp;md5=198ddd1999d89e1bc42240f5c9798377\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of\u00a0the United States\u00a0and\u00a0Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=153087c5ebc594657868d8173eaeed99\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=05694ea5753994ba98e9a82ff92cc9f8\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=f59eb262f289d0c9ad328de388988bf3\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=b0e5fb7818137e77e25e9ac71e1b5d1f\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=582b15b22b38e27ff9080ebbec36f714\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=8110a482d4750082bd4ede0371418d01\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=8671b895729201d71cc478716c08215b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for LENVIMA (lenvatinib) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lenvima.com%2Fpdfs%2Fprescribing-information.pdf&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.lenvima.com%2Fpdfs%2Fprescribing-information.pdf&amp;index=11&amp;md5=c3cea8b63accc2a163c4b496958bf730\" rel=\"nofollow\"><br \/>\n<b>http:\/\/www.lenvima.com\/pdfs\/prescribing-information.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=12&amp;md5=1f163b924c92b99a5213e1c856201eff\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>\u00a0and<br \/>\n      Medication Guide for KEYTRUDA at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51845214&amp;newsitemid=20180731005341&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=13&amp;md5=3269cf4fadfa0027ea09421e70d24806\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180731005341r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Eisai Public Relations Department <br \/>+81-(0)3-3817-5120<br \/>Neriman        Botas, (201) 746-2073<br \/>or<br \/> Eisai Investor Relations <br \/>+81-(0)3-3817-3016<br \/>or<br \/> Merck        Media Relations <br \/>Pamela Eisele, (267) 305-3558<br \/>Ann Bush,        (908) 740-6677<br \/>or<br \/> Merck Investor Relations <br \/>Teri        Loxam, (908) 740-1986<br \/>Michael DeCarbo, (908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for LENVIMA \u00ae (lenvatinib), the orally available kinase inhibitor discovered by Eisai, in combination with Merck&#8217;s anti-PD-1 therapy KEYTRUDA \u00ae (pembrolizumab) for the potential treatment of patients with advanced and\/or metastatic non-microsatellite instability high (MSI-H)\/proficient mismatch repair (pMMR) endometrial carcinoma (EC) who have progressed following at least one prior systemic therapy. The LENVIMA\/KEYTRUDA combination therapy is being jointly developed by Eisai and Merck as part of the strategic collaboration announced in March 2018. This is the third Breakthrough Therapy designation for LENVIMA and the second Breakthrough Therapy designation for LENVIMA in combination with KEYTRUDA, following the Breakthrough Therapy designation for the combination for advanced and\/or<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-745685","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for LENVIMA \u00ae (lenvatinib), the orally available kinase inhibitor discovered by Eisai, in combination with Merck&#039;s anti-PD-1 therapy KEYTRUDA \u00ae (pembrolizumab) for the potential treatment of patients with advanced and\/or metastatic non-microsatellite instability high (MSI-H)\/proficient mismatch repair (pMMR) endometrial carcinoma (EC) who have progressed following at least one prior systemic therapy. The LENVIMA\/KEYTRUDA combination therapy is being jointly developed by Eisai and Merck as part of the strategic collaboration announced in March 2018. This is the third Breakthrough Therapy designation for LENVIMA and the second Breakthrough Therapy designation for LENVIMA in combination with KEYTRUDA, following the Breakthrough Therapy designation for the combination for advanced and\/or\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"34 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\\\/\",\"name\":\"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\\\/or Metastatic non-MSI-H\\\/pMMR Endometrial Carcinoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-07-31T05:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\\\/or Metastatic non-MSI-H\\\/pMMR Endometrial Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/","og_locale":"en_US","og_type":"article","og_title":"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma - Merck.com","og_description":"Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for LENVIMA \u00ae (lenvatinib), the orally available kinase inhibitor discovered by Eisai, in combination with Merck's anti-PD-1 therapy KEYTRUDA \u00ae (pembrolizumab) for the potential treatment of patients with advanced and\/or metastatic non-microsatellite instability high (MSI-H)\/proficient mismatch repair (pMMR) endometrial carcinoma (EC) who have progressed following at least one prior systemic therapy. The LENVIMA\/KEYTRUDA combination therapy is being jointly developed by Eisai and Merck as part of the strategic collaboration announced in March 2018. This is the third Breakthrough Therapy designation for LENVIMA and the second Breakthrough Therapy designation for LENVIMA in combination with KEYTRUDA, following the Breakthrough Therapy designation for the combination for advanced and\/or","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:08+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"34 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/","name":"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-07-31T05:30:00+00:00","dateModified":"2025-11-07T06:27:08+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA\u00ae (lenvatinib) in Combination with KEYTRUDA\u00ae (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and\/or Metastatic non-MSI-H\/pMMR Endometrial Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5893c6a2-7a4d-4134-9462-d797575554b2","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745685\/revisions"}],"predecessor-version":[{"id":3675030,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745685\/revisions\/3675030"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745685"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}